Skip to main content
SpringerLink
Log in

New Dietary Supplements for Obesity: What We Currently Know

  • Obesity Treatment (CM Apovian, Section Editor)
  • Published:
Current Obesity Reports Aims and scope Submit manuscript

Abstract

Obesity and its associated cardiometabolic alterations currently are considered an epidemic; thus, their treatment is of major importance. The cornerstone for such treatment involves therapeutic lifestyle changes; however, the vast majority of cases fail and/or significant weight loss is maintained only in the short term because of lack of compliance. The popularity of dietary supplements for weight management has increased, and a wide variety of these products are available over the counter. However, the existing scientific evidence is insufficient to recommend their safe use. Hence, the purpose of this article is to review the clinical effects, proposed mechanism of action, and safety profile of some of the new dietary supplements, including white bean extract, Garcinia cambogia, bitter orange, Hoodia gordonii, forskolin, green coffee, glucomannan, β-glucans, chitosan, guar gum, and raspberry ketones.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Bradley J. NBJ: “The US supplement industry is $37 billion, not $12 billion” [Internet]. Nutr Bus J. 2015. Available from: URL: http://www.nutraingredients-usa.com/Markets/NBJ-The-US-supplement-industry-is-37-billion-not-12-billion.

  2. Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. US Dep Heal Hum Serv. 1994; Available from: URL: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003.htm#sec3.

  3. Food and Drug Administration. What is a dietary supplement? [Internet]. 2015. Available from: URL: http://www.fda.gov/AboutFDA/Transparency/Basics/ucm195635.htm.

  4. Geller A, Shehab N, Weidle N, Lovegrove M, Wolpert B, Timbo B, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531–40. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.

  5. Stohs SJ, Preuss HG, Shara M. The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p‐synephrine. Phytother Res. 2011;25:1421–8.

    Article  CAS  PubMed  Google Scholar 

  6. Fugh-Berman A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med. 2004;229:698–704.

    CAS  Google Scholar 

  7. Allison DB, Cutter G, Poehlman ET, Moore DR, Barnes S. Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain? Int J Obes (Lond). 2005;29:443–6.

    Article  CAS  Google Scholar 

  8. Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006;7:79–88.

    Article  CAS  PubMed  Google Scholar 

  9. Colker CM, Kalman DS, Torina GC, Perlis T, Street C. Effects of Citrus aurantium extract, caffeine, and St. John’s Wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res. 1999;60:145–53.

    Article  Google Scholar 

  10. Kalman DS, Colker CM, Shi QH, Swain MA. Effects of a weight-loss aid in healthy overweight adults: double-blind, placebo-controlled clinical trial. Curr Ther Res Exp. 2000;61:199–205.

    Article  Google Scholar 

  11. Stohs SJ, Preuss HG, Keith SC, Keith PL, Miller H, Kaats GR. Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int J Med Sci. 2011;8:295–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kim G-S, Park HJ, Woo J-H, Kim M-K, Koh P-O, Min W, et al. Citrus aurantium flavonoids inhibit adipogenesis through the Akt signaling pathway in 3T3-L1 cells. BMC Complement Altern Med [Internet]. 2012;12:31.

    Article  CAS  Google Scholar 

  13. Bent S, Padula A, Neuhaus J. Safety and efficacy of Citrus aurantium for weight loss. Am J Cardiol. 2004;94:1359–61.

    Article  PubMed  Google Scholar 

  14. Kaats GR, Miller H, Preuss HG, Stohs SJ. A 60day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract. Food Chem Toxicol. 2013;55:358–62.

    Article  CAS  PubMed  Google Scholar 

  15. Stohs SJ. Assessment of the adverse event reports associated with Citrus aurantium (bitter orange) from April 2004 to October 2009. J Funct Foods. 2010;2:235–8.

    Article  Google Scholar 

  16. Russell PJ, Swindells C. Chemical characterisation of Hoodia gordonii extract. Food Chem Toxicol. 2012;50(S):6–13.

    Article  Google Scholar 

  17. Van Heerden FR. Hoodia gordonii: a natural appetite suppressant. J Ethnopharmacol. 2008;119:434–7.

    Article  PubMed  Google Scholar 

  18. Smith C, Krygsman A. Hoodia gordonii: to eat, or not to eat. J Ethnopharmacol. 2014;155:987–91.

    Article  PubMed  Google Scholar 

  19. MacLean DB, Luo LG. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res. 2004;1020:1–11.

    Article  CAS  PubMed  Google Scholar 

  20. Le Nevé B, Foltz M, Daniel H, Gouka R. The steroid glycoside H.g.-12 from Hoodia gordonii activates the human bitter receptor TAS2R14 and induces CCK release from HuTu-80 cells. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1368–75.

    Article  PubMed  Google Scholar 

  21. Blom WAM, Abrahamse SL, Bradford R, Duchateau GSMJE, Theis W, Orsi A, et al. Effects of 15-d repeated consumption of Hoodia gordonii purified extract on safety, ad libitum energy intake, and body weight in healthy, overweight women: a randomized controlled trial. Am J Clin Nutr. 2011;94:1171–81.

    Article  CAS  PubMed  Google Scholar 

  22. Yamoneka J, Malumba P, Blecker C, Gindo M, Richard G, Fauconnier M-L, et al. Physicochemical properties and thermal behaviour of African wild mango (Irvingia gabonensis) seed fat. LWT - Food Sci Technol. 2015;64:989–96.

    Article  CAS  Google Scholar 

  23. Ribeiro SMR, Barbosa LCA, Queiroz JH, Knödler M, Schieber A. Phenolic compounds and antioxidant capacity of Brazilian mango (Mangifera indica L.) varieties. Food Chem. 2008;110:620–6.

    Article  CAS  Google Scholar 

  24. Arogba SS. Phenolics, antiradical assay and cytotoxicity of processed mango (Mangifera indica) and bush mango (Irvingia gabonensis) kernels. Niger Food J. 2014;32:62–72.

    Article  Google Scholar 

  25. Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis. 2008;7:44.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ngondi JL, Oben JE, Minka SR. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids Health Dis. 2005;4:12.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Oben JE, Ngondi JL, Momo CN, Agbor GA, Sobgui CSM. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis. 2008;7:12.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Onakpoya I, Davies L, Posadzki P, Ernst E. The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials. J Diet Suppl. 2013;10:29–38.

    Article  PubMed  Google Scholar 

  29. Farah A, Donangelo CM. Phenolic compounds in coffee. Brazilian J Plant Physiol. 2006;18:23–36.

    Article  CAS  Google Scholar 

  30. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2:1231–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mullin G. Supplements for weight loss: hype or help for obesity? Part II. The inside scoop on green coffee bean extract. Nutr Clin Pract. 2015;30:311–2. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.

  32. Flanagan J, Bily A, Rolland Y, Roller M. Lipolytic activity of Svetol®, a decaffeinated green coffee bean extract. Phytother Res. 2014;28:946–8.

    Article  CAS  PubMed  Google Scholar 

  33. Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med. 2006;6:9.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, et al. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010;48:937–43.

    Article  CAS  PubMed  Google Scholar 

  35. Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011;2011:1–6.

    Article  Google Scholar 

  36. Kavitha C, Rajamani K, Vadivel E. Coleus forskohlii: a comprehensive review on morphology, phytochemistry and pharmacological aspects. J Med Plants Res. 2010;4:278–85.

    CAS  Google Scholar 

  37. Insel PA, Ostrom RS. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol. 2003;23:305–14.

    Article  CAS  PubMed  Google Scholar 

  38. Godard MP, Johnson BA, Richmond SR. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res. 2005;13:1335–43.

    Article  CAS  PubMed  Google Scholar 

  39. Henderson S, Magu B, Rasmussen C, Lancaster S, Kerksick C, Smith P, et al. Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. J Int Soc Sports Nutr. 2005;2:54–62.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Peng J, Yuan JP, Wu CF, Wang JH. Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs. 2011;9:1806–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Hu X, Li Y, Li C, Fu Y, Cai F, Chen Q, et al. Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lipid metabolism in high-fat diet-induced obese rats. Arch Biochem Biophys. 2012;519:59–65.

    Article  CAS  PubMed  Google Scholar 

  42. Beppu F, Hosokawa M, Niwano Y, Miyashita K. Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-Ay mice. Lipids Health Dis. 2012;11:112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wu M, Singh SB, Wang J, Chung CC, Salituro G, Karanam BV, et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci. 2011;108:5378–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Gammone MA, D’Orazio N. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs. 2015;13:2196–214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kang S-I, Ko H-C, Shin H-S, Kim H-M, Hong Y-S, Lee N-H, et al. Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes. Biochem Biophys Res Commun. 2011;409:769–74.

    Article  CAS  PubMed  Google Scholar 

  46. D’Orazio N, Gemello E, Gammone MA, De Girolamo M, Ficoneri C, Riccioni G. Fucoxantin: a treasure from the sea. Mar Drugs. 2012;10:604–16.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun. 2005;332:392–7.

    Article  CAS  PubMed  Google Scholar 

  48. Buras E. The effects of XanthigenTM supplementation on body composition, serum markers of the metabolic syndrome, and hepaptic enzyme levels in an obese population. Honors Theses. The University of Southern Mississippi; 2012.

  49. Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of XanthigenTM in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab. 2010;12:72–81.

    Article  CAS  PubMed  Google Scholar 

  50. Bredsdorff L, Wedebye EB, Nikolov NG, Hallas-Møller T, Pilegaard K. Raspberry ketone in food supplements—high intake, few toxicity data—a cause for safety concern? Regul Toxicol Pharmacol. 2015;73:196–200.

    Article  CAS  PubMed  Google Scholar 

  51. Park KS. Raspberry ketone increases both lipolysis and fatty acid oxidation in 3T3-L1 adipocytes. Planta Med. 2010;76:1654–8.

    Article  CAS  PubMed  Google Scholar 

  52. Park KS. Raspberry ketone, a naturally occurring phenolic compound, inhibits adipogenic and lipogenic gene expression in 3T3-L1 adipocytes. Pharm Biol. 2015;53:870–5. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.

  53. Morimoto C, Satoh Y, Hara M, Inoue S, Tsujita T, Okuda H. Anti-obese action of raspberry ketone. Life Sci. 2005;77:194–204.

    Article  CAS  PubMed  Google Scholar 

  54. Alonso-Sande M, Teijeiro-Osorio D, Remuñán-López C, Alonso MJ. Glucomannan, a promising polysaccharide for biopharmaceutical purposes. Eur J Pharm Biopharm. 2009;72:453–62.

    Article  CAS  PubMed  Google Scholar 

  55. Davé V, McCarthy S. Review of konjac glucomannan. J Polym Environ. 1997;5:237–41.

    Google Scholar 

  56. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11:30–4.

    PubMed  Google Scholar 

  57. Keithley JK, Swanson B, Mikolaitis SL, DeMeo M, Zeller JM, Fogg L, et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes. 2013;2013:610908.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014;33:70–8.

    Article  CAS  PubMed  Google Scholar 

  59. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88:1167–75.

    CAS  PubMed  Google Scholar 

  60. Cloetens L, Ulmius M, Johansson-Persson A, Åkesson B, Önning G. Role of dietary beta-glucans in the prevention of the metabolic syndrome. Nutr Rev. 2012;70:444–58.

    Article  PubMed  Google Scholar 

  61. El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362.

    PubMed  PubMed Central  Google Scholar 

  62. Synytsya A, Míčková K, Synytsya A, Jablonský I, Spěváček J, Erban V, et al. Glucans from fruit bodies of cultivated mushrooms Pleurotus ostreatus and Pleurotus eryngii: structure and potential prebiotic activity. Carbohydr Polym. 2009;76:548–56.

    Article  CAS  Google Scholar 

  63. Maki KC, Galant R, Samuel P, Tesser J, Witchger MS, Ribaya-Mercado JD, et al. Effects of consuming foods containing oat beta-glucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. Eur J Clin Nutr. 2007;61:786–95.

    Article  CAS  PubMed  Google Scholar 

  64. Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher RG, Slavin JL. Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutr J. 2007;6:6.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Davy BM, Melby CL, Beske SD, Ho RC, Davrath LR, Davy KP. Oat consumption does not affect resting casual and ambulatory 24-h arterial blood pressure in men with high-normal blood pressure to stage I hypertension. J Nutr. 2002;132:394–8.

    CAS  PubMed  Google Scholar 

  66. Kabir M, Oppert J-M, Vidal H, Bruzzo F, Fiquet C, Wursch P, et al. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism. 2002;51:819–26.

    Article  CAS  PubMed  Google Scholar 

  67. Lyly M, Liukkonen KH, Salmenkallio-Marttila M, Karhunen L, Poutanen K, Lähteenmäki L. Fibre in beverages can enhance perceived satiety. Eur J Nutr. 2009;48:251–8.

    Article  CAS  PubMed  Google Scholar 

  68. Lyly M, Ohls N, Lähteenmäki L, Salmenkallio-Marttila M, Liukkonen K-H, Karhunen L, et al. The effect of fibre amount, energy level and viscosity of beverages containing oat fibre supplement on perceived satiety. Food Nutr Res. 2010;54:1–8.

    Article  Google Scholar 

  69. Willis HJ, Eldridge AL, Beiseigel J, Thomas W, Slavin JL. Greater satiety response with resistant starch and corn bran in human subjects. Nutr Res. 2009;29:100–5.

    Article  CAS  PubMed  Google Scholar 

  70. Kim H, Behall KM, Vinyard B, Conway JM. Short-term satiety and glycemic response after consumption of whole grains with various amounts of beta-glucan. Cereal Foods World. 2006;51:29–33.

    CAS  Google Scholar 

  71. Peters HPF, Boers HM, Haddeman E, Melnikov SM, Qvyjt F. No effect of added ß-glucan or of fructooligosaccharide on appetite or energy intake. Am J Clin Nutr. 2009;89:58–63.

    Article  CAS  PubMed  Google Scholar 

  72. Mudgil D, Barak S, Khatkar B. Guar gum: processing, properties and food applications: a review. J Food Sci Technol. 2014;51:409–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Pasman WJ, Westerterp-Plantenga MS, Muls E, Vansant G, van Ree J, Saris WH. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J Obes Relat Metab Disord. 1997;21:548–55.

    Article  CAS  PubMed  Google Scholar 

  74. Pittler MH, Ernst E. Guar gum for body weight reduction: meta-analysis of randomized trials. Am J Med. 2001;110:724–30.

    Article  CAS  PubMed  Google Scholar 

  75. Dall’Alba V, Silva FM, Antonio JP, Steemburgo T, Royer CP, Almeida JC, et al. Improvement of the metabolic syndrome profile by soluble fibre—guar gum—in patients with type 2 diabetes: a randomised clinical trial. Br J Nutr. 2013;110:1601–10.

    Article  PubMed  Google Scholar 

  76. Mattes RD. Effects of a combination fiber system on appetite and energy intake in overweight humans. Physiol Behav. 2007;90:705–11.

    Article  CAS  PubMed  Google Scholar 

  77. Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician. 2004;70:1731–8.

    PubMed  Google Scholar 

  78. Van Bennekum AM, Nguyen DV, Schulthess G, Hauser H, Phillips MC. Mechanisms of cholesterol-lowering effects of dietary insoluble fibres: relationships with intestinal and hepatic cholesterol parameters. Br J Nutr. 2005;94:331–7.

    Article  PubMed  Google Scholar 

  79. Ernst E, Pittler MH. Chitosan as a treatment for body weight reduction? A meta-analysis. Perfusion. 1998;11:461–5.

    Google Scholar 

  80. Pereira A, Guedes AD, Verreschi ITN, Santos RD, Martinez TLR. Obesity and its association with other cardiovascular risk factors in school children in Itapetininga. Brazil Arq Bras Cardiol. 2009;93:253–60.

    PubMed  Google Scholar 

  81. Schiller RN, Barrager E, Schauss AG, Nichols EJ. A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. JANA. 2001;4:42–9.

    Google Scholar 

  82. Mhurchu CN, Poppitt SD, McGill A-T, Leahy FE, Bennett DA, Lin RB, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004;28:1149–56.

    Article  CAS  PubMed  Google Scholar 

  83. Guerciolini R, Radu-Radulescu L, Boldrin M, Dallas J, Moore R. Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. Obes Res. 2001;9:364–7.

    Article  CAS  PubMed  Google Scholar 

  84. Vinson J, Kharrat HA, Shuta D. Investigation of an amylase inhibitor on human glucose absorption after starch consumption. Open Nutraceuticals J. 2009;2009:88–91.

    Article  Google Scholar 

  85. Celleno L, Tolaini MV, D’Amore A, Perricone NV, Preuss HG. A Dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci. 2007;4:45–52.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Onakpoya I, Aldaas S, Terry R, Ernst E. The efficacy of Phaseolus vulgaris as a weight-loss supplement: a systematic review and meta-analysis of randomised clinical trials. Br J Nutr. 2011;106:196–202.

    Article  CAS  PubMed  Google Scholar 

  87. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998;280:1596–600.

    Article  CAS  PubMed  Google Scholar 

  88. Astell KJ, Mathai ML, Su XQ. Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials. Complement Ther Med. 2013;21:407–16.

    Article  PubMed  Google Scholar 

  89. De Lira-Garcia C, Souto-Gallardo M, Bacardi-Gascon M, Jimenez-Cruz A. A systematic review of the effectiveness of alternative weight-loss products’ ingredients. Rev Salud Publica (Bogota). 2008;10:818–30.

    Article  Google Scholar 

  90. Kim K-Y, Lee HN, Kim YJ, Park T. Garcinia cambogia extract ameliorates visceral adiposity in C57BL/6J mice fed on a high-fat diet. Biosci Biotechnol Biochem. 2008;72:1772–80.

    Article  CAS  PubMed  Google Scholar 

  91. Kim YJ, Choi MS, Park YB, Kim SR, Lee MK, Jung UJ. Garcinia cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol. 2013;19:4689–701.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Lobb A. Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World J Gastroenterol. 2009;15:1786–7.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Márquez F, Babio N, Bulló M, Salas-Salvadó J. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Crit Rev Food Sci Nutr. 2012;52:585–94.

    Article  PubMed  Google Scholar 

  94. Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015;102:134–48.

    Article  CAS  PubMed  Google Scholar 

  95. Pittler M, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr. 2004;79:529–36.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Av. Universidad Anáhuac #46. Lomas Anáhuac, 52786, Huixquilucan, Estado de México, México

    Alejandro Ríos-Hoyo & Gabriela Gutiérrez-Salmeán

Authors
  1. Alejandro Ríos-Hoyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriela Gutiérrez-Salmeán
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriela Gutiérrez-Salmeán.

Ethics declarations

Conflict of Interest

Alejandro Ríos-Hoyo and Gabriela Gutiérrez-Salmeán declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Obesity Treatment

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ríos-Hoyo, A., Gutiérrez-Salmeán, G. New Dietary Supplements for Obesity: What We Currently Know. Curr Obes Rep 5, 262–270 (2016). https://doi.org/10.1007/s13679-016-0214-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13679-016-0214-y

Keywords

Search

Navigation